- Investing.com
Strategic Pivot | HOOKIPA's 80% workforce reduction and pausing of lead program signal a major shift towards focusing on high-potential areas like the HB-700 KRAS vaccine |
Pipeline Prospects | Explore HOOKIPA's ongoing collaborations with Gilead Sciences in HIV and HBV vaccines, offering potential milestone payments and royalties |
Financial Challenges | Delve into HOOKIPA's financial position, with cash reserves and partnerships offsetting concerns about long-term stability and weak profit margins |
Market Outlook | Analyst price targets range from $5 to $48, reflecting mixed sentiments on HOOKIPA's future amid restructuring and pipeline developments |
Metrics to compare | HOOK | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipHOOKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −4.2x | −0.4x | |
PEG Ratio | 0.01 | −0.23 | 0.00 | |
Price/Book | 0.4x | 2.3x | 2.6x | |
Price / LTM Sales | 1.4x | 15.0x | 3.0x | |
Upside (Analyst Target) | 90.5% | 106.4% | 55.7% | |
Fair Value Upside | Unlock | 6.5% | 8.1% | Unlock |